Sino Biopharmaceutical Ltd. (HKG: 1177) announced it has agreed to acquire a 100 % equity stake in Hygieia Pharmaceuticals for a maximum base consideration of RMB 1.2 billion (USD 172 million), adding a pipeline of innovative small interfering RNA (siRNA) drugs targeting weight loss, cardiovascular, and nervous system disorders to its portfolio.
Contents
Deal Structure
| Item | Detail |
|---|---|
| Acquirer | Sino Biopharmaceutical Ltd. (HKEX: 1177) |
| Target | Hygieia Pharmaceuticals (private) |
| Equity | 100 % stake |
| Base Consideration | RMB 1.2 billion (USD 172 million) |
| Structure | All‑cash transaction |
| Payment | To be completed upon regulatory approvals (expected Q2 2026) |
| Earn‑out | Up to RMB 300 million in milestones tied to Phase III initiation and NDA approvals |
Target Profile & siRNA Platform
- Technology: Small interfering RNA (siRNA) platform enabling long‑lasting target gene silencing with single or infrequent administrations
- Therapeutic Areas:
- Weight loss/metabolism
- Cardiovascular/cerebrovascular
- Nervous system disorders
- Pipeline: 4 clinical‑stage assets and 10+ preclinical molecules with first‑in‑class (FIC) or best‑in‑class (BIC) potential
Core Pipeline Assets
| Drug | Target | Dosing | Indication | Stage |
|---|---|---|---|---|
| Kylo‑11 | Lp(a) siRNA | Once yearly | Cardiovascular disease | Phase II |
| Kylo‑12 | APOC3 siRNA | Every 6 months | Hypertriglyceridemia (HTG), FCS | Phase II‑ready |
| Preclinical | Undisclosed siRNA | Once yearly | Obesity | Preclinical |
| Preclinical | Undisclosed siRNA | Every 6 months | Alzheimer’s disease | Preclinical |
Market Opportunity & Competitive Landscape
| Parameter | China | Global |
|---|---|---|
| Hyperlipidemia Patients (Lp(a) elevation) | 25 million | 90 million |
| Severe HTG/FCS Patients | 1.2 million | 4.5 million |
| Obesity (Class II/III) | 85 million | 650 million |
| Alzheimer’s Disease | 10 million | 55 million |
| siRNA Market (2030E) | ¥28 billion | $18 billion |
| Hygieia Peak Revenue (2032E) | ¥4.2 billion | $2.8 billion |
- Competitive Moat: Hygieia’s ultra‑long‑acting dosing (once yearly for Lp(a), every 6 months for APOC3) vs. competitors requiring monthly or quarterly injections (e.g., Novartis’s Leqvio)
- Strategic Value: Acquisition provides Sino Biopharmaceutical with first‑in‑China siRNA platform, leapfrogging domestic competitors in chronic disease RNA therapeutics
Strategic Positioning & Synergies
- Sino’s Platform: Complements Sino’s existing metabolic disease franchise (diabetes, NASH) and CNS pipeline (stroke, Parkinson’s)
- Manufacturing: Sino’s Shanghai biologics facility will integrate Hygieia’s siRNA conjugation and LNP formulation capabilities by 2027
- Commercial Reach: Sino’s 3,000‑person sales force targeting tier‑2/3 hospitals can rapidly launch Kylo‑11/12 upon approval
- Global Ambitions: Hygieia’s platform enables ex‑China licensing to MNCs; Sino plans US IND filings for Kylo‑11 in 2027
Forward‑Looking Statements
This brief contains forward‑looking statements regarding acquisition completion, pipeline development timelines, and revenue forecasts for Hygieia’s siRNA platform. Actual results may differ due to regulatory approval timelines, clinical trial outcomes, and competitive dynamics in the RNA therapeutics market.-Fineline Info & Tech